Paxlovid May Reduce Risk of Long COVID, Study Suggests
A recent study has brought to light the potential of Paxlovid, an antiviral treatment for COVID-19, to significantly reduce the risk of long COVID. The research, which has been published online but awaits peer review, analyzed medical records from the U.S. Department of Veterans Affairs, focusing on 56,340 patients who tested positive for COVID-19 between March and June 2022 and had at least one risk factor for severe COVID-19.
Key Findings:
- Reduction in Long COVID Risk: Patients who took Paxlovid within five days of being diagnosed with COVID-19 had a 26% lower risk of experiencing long-term symptoms such as fatigue, shortness of breath, cognitive issues, and muscle pain, as well as kidney, liver, and heart problems.
- Effectiveness Across Vaccination Statuses: The antiviral was beneficial regardless of vaccination status, with unvaccinated, vaccinated, and boosted individuals all showing a lower risk of developing long COVID if they took Paxlovid.
- Lower Hospitalization and Mortality Rates: Those who took Paxlovid were also 30% less likely to be hospitalized and 48% less likely to die.
How Paxlovid Works: Paxlovid inhibits the virus's ability to replicate in the body, reducing the viral load and potentially lowering the likelihood of the immune system producing auto-antibodies that can damage healthy tissues and organs. It may also hasten the body's clearance of the virus, reducing the chance of lingering symptoms.
Considerations and Future Research: While the findings are promising, questions remain about Paxlovid's effectiveness in generally healthy individuals, the optimal timing for starting treatment, and its applicability across all races and ethnicities. Further studies are needed to validate these findings and explore additional aspects of Paxlovid's impact on long COVID.
Conclusion: The study offers a compelling reason for more people to consider Paxlovid, especially those at higher risk of severe COVID-19. It underscores the importance of early treatment in potentially reducing the incidence of long COVID, a condition that has been disabling millions worldwide.